JP2019526274A - 抗マラリアワクチンとしてのバイオ融合タンパク質 - Google Patents

抗マラリアワクチンとしてのバイオ融合タンパク質 Download PDF

Info

Publication number
JP2019526274A
JP2019526274A JP2019524114A JP2019524114A JP2019526274A JP 2019526274 A JP2019526274 A JP 2019526274A JP 2019524114 A JP2019524114 A JP 2019524114A JP 2019524114 A JP2019524114 A JP 2019524114A JP 2019526274 A JP2019526274 A JP 2019526274A
Authority
JP
Japan
Prior art keywords
msp3
sequence
protein
antigenic
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019524114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526274A5 (enExample
Inventor
ドリュイル，ピエール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vac4all Pte Ltd
Original Assignee
Vac4all Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vac4all Pte Ltd filed Critical Vac4all Pte Ltd
Publication of JP2019526274A publication Critical patent/JP2019526274A/ja
Publication of JP2019526274A5 publication Critical patent/JP2019526274A5/ja
Priority to JP2022085159A priority Critical patent/JP7579298B2/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019524114A 2016-07-21 2017-07-21 抗マラリアワクチンとしてのバイオ融合タンパク質 Pending JP2019526274A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022085159A JP7579298B2 (ja) 2016-07-21 2022-05-25 抗マラリアワクチンとしてのバイオ融合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16180544.5 2016-07-21
EP16180544 2016-07-21
PCT/SG2017/050369 WO2018017020A1 (en) 2016-07-21 2017-07-21 Biofusion proteins as anti-malaria vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022085159A Division JP7579298B2 (ja) 2016-07-21 2022-05-25 抗マラリアワクチンとしてのバイオ融合タンパク質

Publications (2)

Publication Number Publication Date
JP2019526274A true JP2019526274A (ja) 2019-09-19
JP2019526274A5 JP2019526274A5 (enExample) 2020-08-27

Family

ID=56550732

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019524114A Pending JP2019526274A (ja) 2016-07-21 2017-07-21 抗マラリアワクチンとしてのバイオ融合タンパク質
JP2022085159A Active JP7579298B2 (ja) 2016-07-21 2022-05-25 抗マラリアワクチンとしてのバイオ融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022085159A Active JP7579298B2 (ja) 2016-07-21 2022-05-25 抗マラリアワクチンとしてのバイオ融合タンパク質

Country Status (10)

Country Link
US (2) US20210038706A1 (enExample)
EP (2) EP4147715A1 (enExample)
JP (2) JP2019526274A (enExample)
KR (2) KR20190090775A (enExample)
CN (1) CN109963586B (enExample)
AU (1) AU2017300965B2 (enExample)
BR (1) BR112019001115A2 (enExample)
CA (1) CA3031399A1 (enExample)
TW (1) TWI780058B (enExample)
WO (1) WO2018017020A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022549791A (ja) * 2019-09-20 2022-11-29 グリフィス・ユニバーシティ ジフテリア毒素交差反応物質（ｃｒｍ）アミノ酸配列を含むタンパク質粒子及びその使用
JP2024510906A (ja) * 2021-02-26 2024-03-12 クラヴァ ウロープ 重症筋無力症の治療的又は予防的処置用のワクチン

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3104833A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.
WO2020033398A1 (en) * 2018-08-06 2020-02-13 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating atii cell-dependent lung diseases
CA3119865A1 (en) * 2018-11-23 2020-05-28 Strike Pharma Ab Bi-specific conjugates
US11052144B2 (en) 2019-04-25 2021-07-06 Dcprime B.V. Methods of tumor vaccination
CN111135290A (zh) * 2020-01-16 2020-05-12 定山石生物科技(北京)有限公司 一种用于激活人体免疫细胞的多肽试剂
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
KR20230135075A (ko) 2021-01-22 2023-09-22 멘두스 비.브이. 종양 백신접종 방법
CN118207228B (zh) * 2024-03-21 2025-03-14 中国科学院上海免疫与感染研究所 一种防治结合的多时期双靶点串联疟疾mRNA疫苗
CN120209159B (zh) * 2025-02-24 2026-08-04 南京澄实生物医药科技有限公司 一种预防疟原虫感染的融合蛋白和免疫原性组合物及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537354A (ja) * 1999-02-25 2002-11-05 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ペプチド、及びＨ．ｉｎｆｌｕｅｎｚａｅのプロテインＤ由来の担体を含む免疫原
JP2006512926A (ja) * 2002-11-12 2006-04-20 スターテンス セルム インスティチュト マラリア・ワクチン
JP2007534650A (ja) * 2003-12-17 2007-11-29 エラン・フアーマシユーチカルズ・インコーポレーテツド Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
JP2014518061A (ja) * 2011-06-01 2014-07-28 シャモン ユニヴァーシティー ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質
JP2016515104A (ja) * 2013-03-08 2016-05-26 ファイザー・インク 免疫原性融合ポリペプチド

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112133A1 (en) * 2003-10-24 2005-05-26 Pierre Druilhe GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537354A (ja) * 1999-02-25 2002-11-05 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ペプチド、及びＨ．ｉｎｆｌｕｅｎｚａｅのプロテインＤ由来の担体を含む免疫原
JP2006512926A (ja) * 2002-11-12 2006-04-20 スターテンス セルム インスティチュト マラリア・ワクチン
JP2007534650A (ja) * 2003-12-17 2007-11-29 エラン・フアーマシユーチカルズ・インコーポレーテツド Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
JP2014518061A (ja) * 2011-06-01 2014-07-28 シャモン ユニヴァーシティー ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質
JP2016515104A (ja) * 2013-03-08 2016-05-26 ファイザー・インク 免疫原性融合ポリペプチド

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DANIEL Y. BARGIERI ET AL.: "New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR", VACCINE, vol. 26, JPN6021018849, 2008, pages 6132 - 6142, ISSN: 0004513487 *
GILLES BANG ET AL.: "Pre-clinical assessment of novel multivalent MSP3 malaria vaccine constructs", PLOS ONE, vol. Vol. 6, Issue 12, e28165, JPN7021001755, 2011, pages 1 - 13, ISSN: 0004513488 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022549791A (ja) * 2019-09-20 2022-11-29 グリフィス・ユニバーシティ ジフテリア毒素交差反応物質（ｃｒｍ）アミノ酸配列を含むタンパク質粒子及びその使用
JP2024510906A (ja) * 2021-02-26 2024-03-12 クラヴァ ウロープ 重症筋無力症の治療的又は予防的処置用のワクチン

Also Published As

Publication number Publication date
TWI780058B (zh) 2022-10-11
AU2017300965B2 (en) 2024-09-12
CN109963586B (zh) 2023-11-03
EP4147715A1 (en) 2023-03-15
AU2017300965A1 (en) 2019-02-07
US20210038706A1 (en) 2021-02-11
JP2022116169A (ja) 2022-08-09
TW201803907A (zh) 2018-02-01
US20220409712A1 (en) 2022-12-29
EP3487526B1 (en) 2022-07-06
BR112019001115A2 (pt) 2019-06-25
WO2018017020A1 (en) 2018-01-25
CN109963586A (zh) 2019-07-02
EP3487526A1 (en) 2019-05-29
JP7579298B2 (ja) 2024-11-07
KR20240154691A (ko) 2024-10-25
KR20190090775A (ko) 2019-08-02
CA3031399A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
JP7579298B2 (ja) 抗マラリアワクチンとしてのバイオ融合タンパク質
Noe et al. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate
JP6199036B2 (ja) 自己タンパク質に対する体液性免疫応答に関わる腫瘍ワクチン接種
Drew et al. Humoral immune responses to DNA vaccines expressing secreted, membrane bound and non-secreted forms of the: Taenia ovis 45W antigen
JP2022037078A (ja) マラリアワクチンにおいて使用するための新規抗原
WO2009082440A2 (en) Compositions of toll-like receptor agonists and malaria antigens and methods of use
EP0880588A2 (fr) Proteine recombinante contenant un fragment c-terminal de msp-1 de plasmodium
Cheong et al. Immunogenicity of bacterial-expressed recombinant Plasmodium knowlesi merozoite surface protein-142 (MSP-142)
EP1885393A2 (en) Methods and compositions for immunizing against chlamydia infection
Mann et al. Protection in a gerbil model of amebiasis by oral immunization with Salmonella expressing the galactose/N-acetyl D-galactosamine inhibitable lectin of Entamoeba histolytica
US12202865B2 (en) Multivalent malaria transmission-blocking vaccines
RU2341534C2 (ru) Иммуногенный гибридный полипептид против ожирения и вакцинная композиция на его основе
WO2018088509A1 (ja) マラリアワクチン
TWI784985B (zh) 瘧疾疫苗
CN102811732B (zh) 免疫原、组合物及其用途和制备方法
WO2017190154A2 (en) Hybrid hepadnavirus cores carrying multiple malaria parasite epitopes
PL212249B1 (pl) Kompleks rybosomalnych bialek P z zarodzca malarii Plasmodium falciparum jako antygen patogenu malarii oraz sposób otrzymania tego antygenu i kaseta ekspresyjna do tego sposobu
WO2024068265A2 (en) Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof
WO2014188212A2 (en) Treatment and prevention of malaria
JP2015514097A (ja) 組換えパパイヤモザイクウイルスコートタンパク質およびインフルエンザワクチンにおけるその使用
CN111658770A (zh) P14.7蛋白质及其作为疫苗佐剂的用途
JP2003277292A (ja) マラリア原虫伝搬阻止粘膜ワクチン
JP2021038159A (ja) Ｒａｇｅ由来ペプチドおよびその使用
Fitri Down-selecting Circumsporozoite Protein-based Malaria Vaccine Formulations: A Comparison of Malaria Sporozoite Challenge Models
JP2005021166A (ja) 抗原タンパク質及び該タンパク質をコードする核酸

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200716

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220125